The Interim guidelines for the treatment of opioid dependence using the new depot buprenorphine formulations are now available.
Developed for NSW Health by Prof Nick Lintzeris, Prof Adrian Dunlop and Debbie Masters, these guidelines provide a framework for clinical decision making by clinicians and consumers in a range of service settings involved in the delivery of treatment with long acting depot buprenorphine products.
The guidelines also contains driving-related information relevant to patients who are receiving the new depot buprenorphine formulations.
The guidelines should be read in conjunction with the NSW Clinical Guidelines: Treatment of Opioid Dependence.
Posted – 8 October 2019